Thursday, March 23, 2023
Rapid advances in biologic therapies have transformed the treatment of psoriasis and inflammatory joint diseases. Agents targeting the interleukin (IL)-23/IL-17 pathway have now the potential to improve both musculoskeletal and skin outcomes. Early identification and treatment initiation are crucial for successful outcomes in psoriasis and spondyloarthritides. Physicians must understand not only the rationale for the development of newer biologic therapies but also the factors influencing biologic selection for individual patients in clinical practice.
Supported by an independent educational grant from UCB Pharma, Inc.
Steering Committee Chair
Professor of Medicine
University of Glasgow
Glasgow, Scotland
Professor of Internal Medicine and Rheumatology
Ruhr-University Bochum
Bochum, Germany
President
Oregon Medical Research Center
Portland, Oregon, United States
Professor of Medicine
University of California
San Francisco
San Francisco, California, United States
Professor and Waldman Chair
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Consultant Rheumatologist
Leeds Teaching Hospitals Trust
Associate Professor
University of Leeds
Leeds, United Kingdom
Associate Professor
Harvard Medical School
Boston, Massachusetts, United States
Professor and Chief
Division of Allergy, Immunology and Rheumatology
University of Rochester Medical Center
Rochester, New York, United States
Consultant Dermatologist
Salford Royal NHS Foundation Trust
Director
Dermatopharmacology Unit
The University of Manchester
Manchester, United Kingdom
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Abbvie; Astra Zeneca; Bristol Myers Squibb; Cabaletta; Causeway; Compugen; Gilead; GlaxoSmithKline; Janssen; Lilly; Moonlake; Novartis; Sanofi; SciRhom; UCB Pharma, Inc.
Speaker or member of speakers bureau for: Abbvie; UCB Pharma, Inc.
Research funding from: Amgen; Astra Zeneca; Bristol Myers Squibb; Boehringer Ingelheim; GlaxoSmithKline; Lilly; UCB Pharma, Inc.
Stock options from: Cabaletta; Evelo; Compugen; Causeway Therapeutics; Step Pharma
Owns stock (privately owned) in: Causeway Therapeutic
Other: NED Evelo
Steering Committee Member
Has no relevant financial relationships.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AbbVie; Abcentra; Aligos; Almirall; Arcutis; Arena; Aslan; Athenex; Boehringer Ingelheim; Bristol-Myers Squibb; Dermavant; EcoR1; Eli Lilly and Company; Evommune; Forte; Galderma; Incyte; Janssen; Landos; Leo; Novartis; Pfizer; Rapt; Regeneron; Sanofi Genzyme; Sun Pharma; UCB Pharma, Inc.; Vibliome; Xencor
Speaker or member of speakers bureau for: AbbVie; UCB Pharma, Inc.
Research funding from: AbbVie; Amgen; Arcutis; Athenex; Boehringer Ingelheim; Bristol-Myers Squibb; Dermavant; Eli Lilly and Company; Galderma; Incyte; Janssen; Leo; Novartis; Pfizer; Regeneron; Sun Pharma; UCB Pharma, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Janssen; Novartis; Pfizer; UCB Pharma, Inc.
Research funding from: Pfizer; Novartis; UCB Pharma, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AnaptysBio; Arcutis, Inc.; Arena Pharmaceuticals; Aristea Therapeutics; Avotres Therapeutics; BioMX; Boehringer-Ingelheim; Brickell Biotech; Castle Biosciences; Corevitas; Dermavant Sciences; Evommune, Inc.; Forte Biosciences; Hexima Ltd.; Meiji Seika Pharma; Mindera; Pfizer; Seanergy; Verrica; Vial
Research funding from: Abbvie; Amgen; Arcutis; Avotres; Boehringer Ingelheim; Cara Therapeutics; Dermavant Sciences; Eli Lilly; Incyte; Inozyme; Janssen Research & Development, LLC; Novartis; Ortho Dermatologics; Regeneron; UCB, Inc
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Lilly; Moonlake; Novartis; Pfizer; UCB
Speaker or member of speakers bureau for: Biogen; Lilly; Janssen; Novartis; UCB
Research funding from: Janssen; Novartis; UCB
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AbbVie; Amgen; Bayer; Biogen; Bristol Myers Squibb Company; Celgene; Janssen; Lilly; Novartis; Pfizer; Sanofi-Regeneron; UCB
Research funding from: Dermavant; LEO; Lilly; Sanofi; UCB
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AbbVie; Bristol Myers Squibb Company; Janssen; Lilly; Novartis; Pfizer; Solarea; UCB
Steering Committee Member
Has no relevant financial relationships.
